The Oncology CRO
Built for Sponsors,
Powered by Technology
Reimagined clinical trials delivering faster and more efficient trials for sponsors
Our experienced CRO executive team works closely with our expert site operations team to continuously review execution strategies, closely monitor patient recruitment efforts, and mitigate key study risks for Oncology clinical trials.
Wendy
Pinson
Director of Oncology
More than 14 years in the biopharma clinical research industry. Leader in clinical operations across oncology, rare disease, GI, infectious disease, autoimmune, OB/GYN, and more.
Connect with Wendy
Richard McCormick Jr.
VP of Oncology
Prominent leader, clinical operations and project management professional with 20+ years of experience specializing in hematology and oncology indications to support complex oncology research for biotech clients.
Powered By Our Connected Technology Platform
Vial CRO delivers faster, more efficient trials
by empowering phenomenal clinical operators
with powerful technology
Vial’s modern technology platform brings clinical trials out of the paper stone age, allowing for streamlined processes inside one end-to-end system.
NGS Integrations
Integrations with leading NGS providers and multi-omics vendors to support targeted oncology sponsors.
No-Nonsense Pricing
Vial offers sponsors fixed-pricing
agreements with no change orders — ever.
Flat-rate pricing
Zero change orders
Risk-share
on commitments
Accountability
on commitments
A fixed-fee pricing model guarantees a set budget for the entirety of a project, regardless of the time and expense that accrues. Vial reserves the right to modify pricing in accordance with amendments to the study design or protocol.
Vial offers fixed upfront pricing to benefit sponsors:
- Align Incentives
- Transparent budget visibility
- No unexpected charges/fees
- Shared accountability on commitments
- Build trust and deepen the relationship
- Experienced team committed to timelines
- Next-generation technology to streamline workflows and process
- A renowned scientific advisory board providing expert insight
- Deep industry relationships and a preferred site network provide an insider view on trial pain points, allowing us to target and prepare to prevent common errors or delays
Tech-Enabled Recruiting Platform
Accelerate Patient Recruiting
Using Multi-Channel Marketing Strategies
and Powerful Technology
We use the most effective digital tools to reach, screen, and enroll motivated subjects quicker. Our optimized process can cut recruitment times in half.
EMR Integrations
HIPAA compliant automated data pulls and Inclusion/Exclusion reviews.
Fast Start-up and Consolidated Site Activation
Vial onboarded 90% of our sites
in less than 30 days
Between our robust technology platform and our team of expert operators, we cut onboarding times in half at nearly every site.
Scientific Advisory Board
Vial CRO is supported by a team of Scientific Advisors who review and provide input on the strategy and direction of the CRO in order to build the infrastructure to advance Oncology research.
Experience across
Immuno-Oncology
The Vial Oncology CRO is supported by a team of scientific advisors with expertise across therapies in immuno-oncology. These advisors provide input on the strategy and direction of the CRO in order to build the infrastructure to advance the research of monoclonal antibodies.
Dr. Neeraj Agarwal
Professor of Medicine and Presidential Endowed Chair of Cancer Research
at the Huntsman Cancer Institute, University of Utah
Dr. Guru Sonpavde
Bladder Cancer Director at the Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard
Medical School
The Vial Oncology CRO is supported by a team of scientific advisors with expertise across therapies in immuno-oncology. These advisors provide input on the strategy and direction of the CRO in order to build the infrastructure to advance the research of cell therapies.
Dr. Arati Rao
Head of Clinical Development at PACT Pharma
The Vial Oncology CRO is supported by a team of scientific advisors with expertise across therapies in immuno-oncology. These advisors provide input on the strategy and direction of the CRO in order to build the infrastructure to advance the research of checkpoint inhibitors.
Dr. Antoni Ribas
Professor of Medicine, Professor of Surgery, and Professor of Molecular and Medical Pharmacology at the University of California Los Angeles (UCLA)
Dr. Guru Sonpavde
Bladder Cancer Director at the Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard
Medical School
Dr. Nathan Pennell
Professor of Medicine and the Director of the Lung Cancer Medical Oncology Program at the Cleveland Clinic Taussig Cancer Institute
Dr. Brian Rini
Chief of Clinical Trials and Professor of Medicine at Vanderbilt University
The Vial Oncology CRO is supported by a team of scientific advisors with expertise across therapies in immuno-oncology. These advisors provide input on the strategy and direction of the CRO in order to build the infrastructure to advance the research of cancer vaccines.
Dr. Guru Sonpavde
Bladder Cancer Director at the Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard
Medical School
Dr. Eric Jonasch
Genitourinary Medical Oncology Professor and Physician at The University of Texas MD Anderson Cancer Center
Upcoming Events
Vial will be at the 64th ASH Annual Meeting
Past Events
Vial will be at the SITC 37th Annual Meeting
Vial will be at WIN Symposium 2022
Vial will be at ENA 2022 34th Symposium
Tech-Enabled Remote Monitoring Part 1
Download our white paper to learn more about each stakeholder’s benefits of tech-enabled trials.
Tech-Enabled Remote Monitoring Part 2
Download our white paper to learn more about each stakeholder’s benefits of tech-enabled trials.
Vial’s Deployment of Modern, Intuitive Electronic Source
Download our latest white paper to learn how utilizing eSource in clinical trials can streamline process, increase efficiency, and minimize errors.
Why Choose Vial's Oncology CRO?
Streamlined oncology clinical trial startup, more predictable patient recruitment, and higher-quality data.
Vial leverages the expertise and abilities of our in-house oncologists and clinical delivery experts to offer oncology sponsors a CRO built for their greatest needs. Vial’s tech-enabled trial management system and seamless operating system ensure that trials are run with maximum efficiency.
We have thoughtfully built our scientific advisory board to include research experienced oncologists who not only have a passion for new oncology therapies, but also an understanding of how to harness the power of precision medicine and clinical data to combat the growing complexity of oncology clinical trials.
Indications
Broad Experience Across Oncology Indications and Phases
- Acute myeloid leukemia (AML)
- Bone marrow transplant
- Breast cancer
- Carcinoma in situ (CIS) bladder cancer
- Cervical cancer
- Chronic lymphocytic leukemia (CLL)
- Chronic myelogenous (or myeloid) leukemia (CML)
- Colorectal cancer
- Endometrial
- Gastrointestinal stromal tumor (GIST)
- Gliomas
- Head and neck cancer
- Hepatocellular carcinoma
- Idiopathic thrombocytopenic purpura (ITP)
- Lymphoma
- Malignant ascites
- Melanoma
- Multiple myeloma
- Myelodysplastic syndrome (MDS)
- Neuroendocrine
- Lung cancer
- oGVHD
- Ovarian cancer
- Pancreatic cancer
- Pediatric cancers
- Prostate cancer
- Renal cell carcinoma
- Sarcoma
Connect with us.
Interested in receiving a proposal from Vial? Leave us a message and some of your contact info and we’ll be in touch with you shortly.
If you’re looking to participate in a clinical trial, please click here
